Literature DB >> 34373557

Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.

Ikko Mito1, Hideyuki Takahashi2, Reika Kawabata-Iwakawa3, Shota Ida1, Hiroe Tada1, Kazuaki Chikamatsu1.   

Abstract

Head and neck squamous carcinoma (HNSCC) is highly infiltrated by immune cells, including tumor-infiltrating lymphocytes and myeloid lineage cells. In the tumor microenvironment, tumor cells orchestrate a highly immunosuppressive microenvironment by secreting immunosuppressive mediators, expressing immune checkpoint ligands, and downregulating human leukocyte antigen expression. In the present study, we aimed to comprehensively profile the immune microenvironment of HNSCC using gene expression data obtained from public database. We calculated enrichment scores of 33 immune cell types based on gene expression data of HNSCC tissues and adjacent non-cancer tissues. Based on these scores, we performed non-supervised clustering and identified three immune signatures-cold, lymphocyte, and myeloid/dendritic cell (DC)-based on the clustering results. We then compared the clinical and biological features of the three signatures. Among HNSCC and non-cancer tissues, human papillomavirus (HPV)-positive HNSCCs exhibited the highest scores in various immune cell types, including CD4+ T cells, CD8+ T cells, B cells, plasma cells, basophils, and their subpopulations. Among the three immune signatures, the proportions of HPV-positive tumors, oropharyngeal cancers, early T tumors, and N factor positive cases were significantly higher in the lymphocyte signature than in other signatures. Among the three signatures, the lymphocyte signature showed the longest overall survival (OS), especially in HPV-positive patients, whereas the myeloid/DC signature demonstrated the shortest OS in these patients. Gene set enrichment analysis revealed the upregulation of several pathways related to inflammatory and proinflammatory responses in the lymphocyte signature. The expression of PRF1, IFNG, GZMB, CXCL9, CXCL10, PDCD1, LAG3, CTLA4, HAVCR2, and TIGIT was the highest in the lymphocyte signature. Meanwhile, the expression of PD-1 ligand genes CD274 and PDCD1LG2 was highest in the myeloid/DC signature. Herein, our findings revealed the transcriptomic landscape of the immune microenvironment that closely reflects the clinical and biological significance of HNSCC, indicating that molecular profiling of the immune microenvironment can be employed to develop novel biomarkers and precision immunotherapies for HNSCC.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34373557     DOI: 10.1038/s41598-021-95718-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

1.  Therapeutic targeting of the tumor microenvironment.

Authors:  Johanna A Joyce
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

2.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

Review 3.  Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region.

Authors:  Hisham Mehanna; Tom Beech; Tom Nicholson; Iman El-Hariry; Christopher McConkey; Vinidh Paleri; Sally Roberts
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.

Authors:  Mia Hashibe; Paul Brennan; Simone Benhamou; Xavier Castellsague; Chu Chen; Maria Paula Curado; Luigino Dal Maso; Alexander W Daudt; Eleonora Fabianova; Leticia Fernandez; Victor Wünsch-Filho; Silvia Franceschi; Richard B Hayes; Rolando Herrero; Sergio Koifman; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Dana Mates; Elena Matos; Ana Menezes; Joshua Muscat; Jose Eluf-Neto; Andrew F Olshan; Peter Rudnai; Stephen M Schwartz; Elaine Smith; Erich M Sturgis; Neonilia Szeszenia-Dabrowska; Renato Talamini; Qingyi Wei; Deborah M Winn; David Zaridze; Witold Zatonski; Zuo-Feng Zhang; Julien Berthiller; Paolo Boffetta
Journal:  J Natl Cancer Inst       Date:  2007-05-16       Impact factor: 13.506

6.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.

Authors:  Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin
Journal:  Lancet       Date:  2019-11-01       Impact factor: 79.321

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

Review 9.  The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses.

Authors:  Alireza Labani-Motlagh; Mehrnoush Ashja-Mahdavi; Angelica Loskog
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  2 in total

1.  Tumor molecular differences associated with outcome disparities of Black patients with head and neck cancer.

Authors:  Hugh A J Kim; Peter Y F Zeng; Alana Sorgini; Mushfiq H Shaikh; Halema Khan; Danielle MacNeil; Mohammed I Khan; Adrian Mendez; John Yoo; Kevin Fung; Pencilla Lang; David A Palma; Joe S Mymryk; John W Barrett; Krupal B Patel; Paul C Boutros; Anthony C Nichols
Journal:  Head Neck       Date:  2022-02-21       Impact factor: 3.821

2.  Identification of Gene-Tyrosine Kinase 2 (TYK2) in Head and Neck Squamous Cell Carcinoma Patients-An Integrated Bioinformatics Approach.

Authors:  Xiaoyan Gong; Fukai Ren
Journal:  Dis Markers       Date:  2022-06-07       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.